BEIJING, June 8, 2012 /PRNewswire-Asia-FirstCall/ -- China Biologic Products, Inc. (NASDAQ: CBPO, “China Biologic” or the “Company”), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the Company has decided to postpone its annual general meeting of shareholders (the “Meeting”) by 28 days. The Meeting was originally scheduled to be held at 10:00 a.m. (local time) on Friday, June 22, 2012 and will now be held at 10:00 a.m. (local time) on Friday, July 20, 2012. Details of the postponed meeting are set out below at the end of this release.
The record date for the Meeting has been changed to the close of business on June 8, 2012. Holders of record of ordinary shares of the Company at the close of business on June 8, 2012 are entitled to notice of, and to vote at, the Meeting.
The postponed Meeting will be held on Friday, July 20, 2012 at 10:00 a.m. (local time) at China Biologic’s offices at 18th Floor, Jialong International Building, 19 Chaoyang Park Road, Chaoyang District, Beijing 100125, People’s Republic of China.
About China Biologic Products, Inc.
China Biologic Products, Inc. (Nasdaq: CBPO), is a leading fully integrated plasma-based biopharmaceutical company in China. The Company’s products are used as critical therapies during medical emergencies and for the prevention and treatment of life-threatening diseases and immune-deficiency related diseases. China Biologic is headquartered in Beijing and manufactures over 20 plasma-based products through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products Co., Ltd. and Guiyang Dalin Biologic Technologies Co., Ltd. The Company also has an equity investment in Xi’an Huitian Blood Products Co., Ltd. The Company sells its products to hospitals and other healthcare facilities in China. For additional information, please see the Company’s website www.chinabiologic.com.
Contact: |
China Biologic Products, Inc.
|
ICR Inc. |
SOURCE China Biologic Products, Inc.
